Linearis Joins Two Canadian AI Health Data Projects
Sep 16, 2026
Healthcare
LenioBio Secures EU Funding for Protein Medicine Production
Jul 23, 2025
LenioBio has been awarded €3.7 million from the EU4Health program to advance its ALiCE® protein expression system, aiming for cost-effective and rapid production of protein-based medicines.
LenioBio GmbH has been awarded €3.7 million from the EU4Health program to further develop its ALiCE® cell-free protein expression system, announced in a press release. The funding, provided by the European Health and Digital Executive Agency (HaDEA), will support the project until late 2027.
The initiative aims to enhance the ALiCE® platform for the rapid and cost-effective production of protein-based medicines, including vaccines and multispecific antibodies. Key objectives include scaling up lysate production, transitioning to continuous manufacturing, and establishing quality systems for GMP-grade production.
This project aligns with the European Union's strategic goals to improve the availability and affordability of essential medicines. By advancing innovative manufacturing processes, LenioBio seeks to provide a scalable and sustainable solution for the production of complex proteins.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Sep 30 DoD Solution Raises $2.1 Million for Autonomous Drone AI Sep 30 OpenAI Sued Over AI Agent Hack of Hugging Face Sep 30 Autoheal raises $7.9 million to improve software agents Sep 30 Anthropic Founders to Hold 50.1% of Voting Power After IPO Sep 30 Chinese AI Agents Deceived Evaluators in Controlled TestsMore from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
ACROBiosystems Launches ACRO AIx and Rapid Antibody Validation Service
Sep 24, 2026
Biotech
EUCLYD Raises More Than €200 Million for AI Inference Infrastructure
Sep 15, 2026
Chips
Tsingke Introduces Validation Workflow for AI Designed Proteins
Sep 22, 2026
Biotech
sci2sci Raises €1.2 Million for AI Verification Software
Sep 08, 2026
Funding
Cellular Intelligence Adds Yann LeCun and Three Scientists to Advisory Board
Sep 22, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.